CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 118 enrolled
Drug / intervention
Metformin +2 moredrug
Likely dose
Metformin 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05373680
NCT05373680Phase 3Completed
CompareCT.gov

Clinical Study Evaluating the Efficacy and Safety of Metformin Versus Empagliflozin for Halting Chronic Kidney Disease Progression

Tanta University·interventional·Posted May 13, 2022·Updated Aug 14, 2025

In Brief

A Phase 3 clinical trial evaluating Metformin, Empagliflozin, and 1 other intervention for Renal Insufficiency, Chronic. Completed, enrolled 118 participants across 2 sites.

Detailed Summary

This randomized controlled trial aims at evaluating the efficacy and safety of the antidiabetics metformin versus empagliflozin on chronic kidney disease (CKD) progression in patients with CKD stages 2 or/and 3.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Insufficiency, Chronic
CountriesEgypt
CollaboratorsMansoura University

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedMay 13, 2022
Enrollment StartJan 1, 2022
Primary CompletionApr 1, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.1 years ago

Interventions

Metformindrug

Patients will receive metformin 1000 mg PO daily added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).

Empagliflozindrug

Patients will receive empagliflozin 10 mg daily PO added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).

Controlother

Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).